Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Baxter and Halozyme report positive HyQ trial data

Baxter and Halozyme report positive HyQ trial data

11th July 2011

Baxter has reported positive new data from a clinical study of HyQ, the facilitated subcutaneous immune globulin product it is developing alongside Halozyme Therapeutics.

Top-line results from the phase III trial have shown that the investigational therapy can offer benefits in preventing infections among patients affected by primary immunodeficiency.

The administration of HyQ is aided by the use of recombinant human hyaluronidase, an enzyme that helps to increase dispersion and absorption of the immune globulin.

Data from this trial supports the conclusions drawn from interim results published last year and will aid Baxter's efforts to secure regulatory approval for the drug in this specification.

Ludwig Hantson, president of Baxter's bioscience business, said: "Completion of this important trial brings us closer to providing an option that can address the needs of patients with immune deficiency disorders."

Last month, the company received a positive opinion from Europe's Committee for Medicinal Products for Human Use for its drug Kiovig to be used as a multifocal motor neuropathy treatment.ADNFCR-8000103-ID-800617229-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.